A novel point mutation in P450c17 (CYP17) causing combined 17 alpha-hydroxylase/17,20-lyase deficiency by Brooke, AM et al.
BRIEF REPORT
A Novel Point Mutation in P450c17 (CYP17) Causing
Combined 17-Hydroxylase/17,20-Lyase Deficiency
A. M. Brooke, N. F. Taylor, J. H. Shepherd, M. E. Gore, T. Ahmad, L. Lin, G. Rumsby,
M. Papari-Zareei, R. J. Auchus, J. C. Achermann, and J. P. Monson
Center for Endocrinology (A.M.B., J.P.M.), William Harvey Research Institute, St. Bartholomew’s Hospital, Queen Mary,
University of London, London EC1A 7BE, United Kingdom; Department of Clinical Biochemistry (N.F.T.), King’s College
Hospital, London SE5 9RS, United Kingdom; Department of Medical Oncology (J.H.S., M.E.G., T.A.), Royal Marsden
Hospital, London SW3 6JJ, United Kingdom; Institute of Child Health and Department of Medicine (L.L., J.C.A.), and
Department of Clinical Biochemistry (G.R.), University College Hospital, London NW1 2BU, United Kingdom; and Division
of Endocrinology (M.P.-Z., R.J.A.), Department of Internal Medicine, University of Texas Southwestern Medical Center,
Dallas, Texas 75390-8857
Context: Combined 17-hydroxylase/17,20-lyase deficiency is a rare
cause of congenital adrenal hyperplasia and hypogonadism. Novel
single amino acid changes in P450c17 provide potentially important
insights into key structural domains for enzyme function.
Objective, Design, and Setting: We report a novel missense mu-
tation in P450c17 in a 17-yr-old female presenting with a malignant
mixed germ cell tumor with yolk sac elements who demonstrated
clinical and biochemical features of combined 17-hydroxylase/17,20-
lyase deficiency.
Methods: Quantitative urinary steroid analysis was performed by
high resolution gas chromatography. All eight coding exons of CYP17
were PCR amplified and sequenced. The position of arginine at codon
96 was modeled using the CYP17 structure 2c17 (www.rcsb.org). The
CYP17 genes were subcloned into pcDNA3, expressed in HEK-293
cells, and chromatographed.
Patient and Results: 17-Hydroxylase deficiency was confirmed by
marked reductions in urinary and serum cortisol, androgens, and
estradiol. Mutational analysis revealed a novel homozygous R96Q
missense mutation in P450c17, affecting an amino acid in a key
substrate-binding region of the enzyme, leading to complete
inactivity.
Conclusion: The description of a second missense mutation at codon
96 (R96W and R96Q) in the substrate-binding region of P450c17
provides strong evidence for the key role of this amino acid in 17-
hydroxylase/17,20-lyase function. An association between a malig-
nant germ cell tumor and 17-hydroxylase deficiency has not been
reported previously, although the presence of gonadoblastoma in the
ovary of a patient with this condition has recently been described.
(J Clin Endocrinol Metab 91: 2428–2431, 2006)
COMBINED 17-HYDROXYLASE/17,20-LYASE deficiencyis a relatively rare cause of congenital adrenal hyper-
plasia first described nearly 40 yr ago (1). Genotypic females
(46,XX)with this condition typically presentwithhypertension,
hypokalemia, absent secondary sexual characteristics, and pri-
mary amenorrhea, whereas genotypic males (46,XY) demon-
strate impaired virilization (complete or partial pseudoher-
maphroditism) and absence of pubertal development.
The gene encoding the dual function P450c17 enzyme,
CYP17 (10q24.3), was cloned in 1987 and encodes eight exons
over 6.4 kb DNA (2–4). Mutations in this gene were first re-
ported in 1988 (5). Since then, approximately 45 different mu-
tations have been described in the coding regions, splice donor
sites (resulting inexonskipping), andspliceacceptor sitesof this
gene in patients with combined 17-hydroxylase/17,20-lyase
deficiency (6). Single amino acid changes in P450c17 are rela-
tively rare, but provide potentially important insight into key
structural domains for enzyme function, and a limited number
of patients with isolated 17,20-lyase deficiency due to P450c17
point mutations have been reported (7–9).
In this study, we describe a novel point mutation in a key
substrate-binding region of P450c17 in a prepubertal 17-yr-
old girl who presented with a malignant germ cell tumor.
Patient and Methods
Laboratory analysis
Quantitative urinary steroid analysis was performed by high reso-
lution gas chromatography as previously described (10).
Mutational analysis
After institutional review board approval and informed consent were
obtained, genomic DNAwas extracted from the patient’s leukocytes. All
eight coding exons of CYP17were PCR amplified using variations of the
primers and conditions described previously (11). PCRs were purified
using exonuclease and shrimp alkaline phosphatase and were se-
quenced directly, forward and reverse, using a BigDye Terminator ver-
sion 1.1 cycle sequencing kit (Applied Biosystems, Warrington, UK).
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Sequencing was performed on a MegaBACE1000 capillary DNA se-
quencer (Amersham Biosciences, Little Chalfont, UK).
Structural modeling and functional studies
The position of arginine at codon 96 was modeled using the CYP17
structure 2c17 (www.rcsb.org). Images were generated with MidasPlus
software on a SiliconGraphics (MountainView,CA) octaneworkstation.
The cDNA for CYP17 mutation R96Q was generated by overlapping
PCR using oligonucleotides T7R96Q-S (5-CTCTGGGCAGCCT-
CAAATGGCAAC-3) and R96Q-AS (5-TTGAGGCTGCCCAGAGAA-
GTCCTTG-5)SP6, and pLW01-c17 as a template (12, 13). HEK-293
cells were seeded in six-well plates and transfected with 1 g pcDNA3-
c17 plasmids using FuGene 6 as previously described (12). Cells were
incubated with 2 ml complete medium containing 0.03–0.1 m preg-
nenolone with 150,000 cpm [3H]pregnenolone (PerkinElmer NEN, Shel-
ton, CT). Aliquots (1 ml) were removed after 2–4 h, extracted, and
chromatographed as described previously (12, 13).
Results
Case report
A 17-yr-old, phenotypically female patient from the
United Arab Emirates came to medical attention because of
abdominal pain and was found to have a mixed germ cell
tumor with yolk sac elements. Remission was achieved with
six cycles of bleomycin, etoposide, cisplatinum chemother-
apy (serum-fetoprotein reduced from12,714 to 5mU/liter).
It was noted that the patient was prepubertal, with normal
female external genitalia, absent axillary and pubic hair, and
primary amenorrhea. Her height was at the third percentile
for her age. Her parents were first cousins. Examination
demonstrated palmar pigmentation, buccal and streak pig-
mentation, and hypertension. Abdominal computed tomog-
raphy revealed bilateral adrenal hyperplasia.
Her karyotype was 46,XX. Serum LH and FSH levels were
32 and 60 IU/liter, respectively, and serum estradiol was 88
pmol/liter (24 pg/ml). Serumpotassiumwas 2.5mmol/liter,
serum bicarbonate was 24 mmol/liter, recumbent serum al-
dosterone was 643 pmol/liter (23.2 ng/dl), and plasma renin
activity was undetectable. Serum dehydroepiandrosterone
(DHEA) sulfate, 17-hydroxyprogesterone (17-OHP), and 11-
deoxycortisol were undetectable; androstenedione and tes-
tosteronewere decreased at 1.1 nmol/liter (0.32g/liter) and
0.4 nmol/liter (0.12 ng/ml), respectively. Serum cortisol was
decreased at 15 nmol/liter (0.54 g/dl) with a 0900 h plasma
ACTH level of 21 g/liter. There was no response of cortisol
or any androgens to standard tetracosactrin stimulation (250
g, iv). A clinical diagnosis of complete 17-hydroxylase
deficiency was supported by measurement of urinary ste-
roids by gas liquid chromatography (10), which showed
grossly elevated corticosterone metabolites (42,925 g/24 h)
and pregnanediol (1,360 g/24 h), and absent cortisol, an-
drostenedione, and dehydroandrosterone metabolites.
The patient commenced reverse circadian prednisolone
treatment (2mg in themorning and 4mg in the evening), and
her hypokalemia and hypertension resolved. Puberty was
induced initially with 5 g ethinyl estradiol daily, increased
gradually to 20 g daily over 18 months, followed by the
addition of levonorgestrel. She remains in remission after 18
months of follow-up.
Mutational analysis, modeling, and functional studies
Mutational analysis revealed a novel homozygous R96Q
missense mutation in P450c17. The parents were consan-
guineous, but were unavailable for investigation. This R96Q
change converts a highly conserved, charged, side chain
amino acid (arginine) to an amino acid with a polar un-
charged side chain (glutamine) in flanking strand 2 of-sheet
1 (Fig. 1). This mutation showed complete loss of P450c17
function (Fig. 2).
Discussion
We describe a novel homozygous R96Q missense muta-
tion in P450c17 affecting an amino acid in a key substrate-
binding region of the enzyme, resulting in complete absence
of 17-hydroxylase/17,20-lyase activity. 17-Hydroxylase
deficiency is an autosomal recessive condition that accounts
for approximately 1% of all cases of congenital adrenal hy-
perplasia (14). The estimated incidence is 1 in 50,000 new-
borns (15). This condition was first described by Biglieri et al.
(1) in an adult female (genotype 46,XX) with hypertension,
hypokalemia, and sexual infantilism. This patient had in-
creased urinary excretion of corticosterone with absence of
17-hydroxylated metabolites. As in the present case, the
lack of sexual development and impaired estrogenization
suggested that P450c17 has 17,20-lyase activity in addition to
its 17-hydroxylase activity, and most patients reported to
date have combined 17-hydroxylase/17,20-lyase deficiency
due to deleterious changes in this P450c17 enzyme system.
The biochemical and structural mechanisms involved in
P450c17 dual function (17-hydroxylase and 17,20-lyase ac-
tivity) are being elucidated, and the localization of critical
domains for enzyme function has been supported by the
FIG. 1. Computer model of human CYP17 (RCSB pdbid 2c17). The
protein backbone is shown in ribbon rendering (yellow), with heme in
red. R96 (blue) protrudes into the cleft that separates the -sheet
domain (right) from the -helical domain (left). The guanidinium
group of R96 appears to form hydrogen bonds with carbonyl groups
of residues A113 and F114 (purple), but not with the side chains.
Removal of this positively charged group, which occurs in mutation
R96Q or R96W, is predicted to destabilize the protein by disrupting
this interaction between the two domains.
Brooke et al. • CYP17 Mutation Causing 17-Hydroxylase/17,20-Lyase Deficiency J Clin Endocrinol Metab, June 2006, 91(6):2428–2431 2429
identification of a limited number of point mutations in the
protein in patients with disorders of steroidogenesis.
Under normal physiological conditions, pregnenolone
and progesterone undergo 17-hydroxylation to 17-
hydroxypregnenolone and 17OHP, respectively. Scission of
the C17,20 carbon bond in 17-hydroxypregnenolone yields
DHEA; however, very little 17OHP is converted to andro-
stenedione, because the human P450c17 enzyme catalyzes
this reaction at only 3% the rate of conversion of 17-
hydroxypregnenolone to DHEA (16). If neither 17-hydrox-
ylase nor 17,20-lyase activity is present, pregnenolone is
converted to mineralocorticoids. If only 17-hydroxylase
activity is present, pregnenolone is converted to cortisol, and
if both activities are present, pregnenolone is converted to
DHEA. The P450 enzyme is bound to the smooth endoplas-
mic reticulum, where it accepts electrons from P450 oxi-
doreductase. Electron transfer for the lyase reaction is pro-
moted by the allosteric action of cytochrome b5, but also
requires phosphorylation of serine residues on P450c17 by a
cAMP-dependent kinase. The availability of electrons seems
to determine whether P450c17 performs only 17-hydroxy-
lation or also 17,20-lyase activity. Optimal functioning of the
redox partner-binding site is particularly important for the
lyase reaction. Thus, pointmutations (e.g.R347H andR358Q)
that change the distribution of surface charges on the redox
binding site of P450c17 impair electron transfer and can
result in isolated 17,20-lyase deficiency with preserved 17-
hydroxylase function (8, 9, 13).
Point mutations resulting in combined 17-hydroxylase/
17,20-lyase deficiency have also provided insight into critical
amino acids involved in dual-enzyme function. To date, ap-
proximately 18 different missense and in-frame point mu-
tations have been described (7). A significant proportion of
these mutations may have arisen due to a genetic founder
effect, rather than through selection advantage of heterozy-
gote carriers (17). For example, in studies of combined 17-
hydroxylase/17,20-lyase deficiency in Brazil, only sevenmu-
tations from 28 unrelated alleles in 19 families were found
(11, 18). TheW406Rmutationwasmore common in southern
Brazilians of Spanish origin, and the R362C mutation was
more common in northern Brazilians of Portuguese origin.
Interestingly, neither of these mutations has been found in
Spain or Portugal, suggesting a founder arriving in Brazil
many years before.
In contrast, a homozygous R96W mutation has been re-
ported previously in two siblings of French Canadian origin
with 46,XY pseudohermaphroditism and combined 17-
hydroxylase/17,20-lyase deficiency (19). Although certain
genetic sequences are more vulnerable to mutation, the oc-
currence of two different point mutations in the same amino
acid suggests that this locus has a particularly important
functional role and is supported by the complete loss of dual
enzyme function reported in studies of P450c17 R96W ac-
tivity. Furthermore, modeling of this amino acid change sug-
gests that this amino acid lies within the flanking strand 2 of
the -sheet 1. Mutation of the charged side chain of arginine
to glutamine would lead to complete inactivity of the
enzyme.
The severity of the clinical disease tends to be milder with
mutations that retain partial catalytic activity, but the age of
onset of hypertension, the degree of hypokalemia, and the
aldosterone production rate appear to vary, even in those
with the same mutation (14). For example, up to 15% of
patients with a diagnosis of 17-hydroxylase deficiency are
normokalemic and normotensive at diagnosis (14) (although
not all of these have had the diagnosis proven by genotyp-
ing). An elevated aldosterone level, as in our patient, is
unusual, but not unique (14), and the relatively normal value
of ACTH is probably due to some glucocorticoid potency of
corticosterone leading to partial suppression of the hypo-
thalamic-pituitary (HPA) axis.
This patient presented with a mixed germ cell tumor. A
gonadoblastoma has previously been described in a 46,XX
Brazilian patient with combined 17-hydroxylase/17,20-
lyase deficiency who presented at 17 yr of age (18). There has
also been another report of a 46,XX patient with 17,20-lyase
deficiency presenting with giant ovarian cysts that were re-
duced in size by GnRH antagonist therapy (20). This asso-
ciation remains likely to be a chance finding, but an aware-
ness of the possible development of gonadal tumors in
patients with disordered gonadal steroidogenesis is
necessary.
Our description of a second missense mutation at codon
96 (R96Q) in the substrate-binding region of P450c17 pro-
vides strong evidence for the key role of this amino acid in
17-hydroxylase/17,20-lyase function.
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FIG. 2. Activity of the CYP17 mutation R96Q. Autoradiogram of a
thin layer chromatogram used to separate [3H]pregnenolone metab-
olites is shown, with the locations of steroids indicated. HEK-293 cells
transfected with cDNAs for mutation R96Q or wild-type CYP17 were
incubated with 0.1 M [3H]pregnenolone for 2–4 h, and medium was
extracted and chromatographed. Wild-type CYP17 converts preg-
nenolone (Preg) to 17-hydroxypregenolone (17Preg) and then to
DHEA; mutation R96Q shows no activity.
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